Current promoter holding is 76.42 % and public share holding is 21.80%. Threfore another buyback at higher price is a clear possibility and it has to come at much higher price whenever it happens.
In addition company is planing to quadruple its business in 5 years ( Reports Business Standard ).
Furthermore it is challenging the denial of patent for Glivec, its blood cancer drug in beta crystal form in The Supreme Court. Any positive outcome will have cascaed effect on stock price.
Institution already exited from this counter during last buyback and resulted less floting stock in the market. Spike in share price is clear possibility if good news start flowing in coming days.
| NIFTY 
